133 related articles for article (PubMed ID: 16254795)
1. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
Kiselyov A
IDrugs; 2005 Oct; 8(10):799-801. PubMed ID: 16254795
[No Abstract] [Full Text] [Related]
2. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Filling the gaps in compound libraries and enhancing compound collections.
Kiselyov A
IDrugs; 2005 Oct; 8(10):802-4. PubMed ID: 16254796
[No Abstract] [Full Text] [Related]
3. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Emerging and early stage company showcase pre-conference symposium.
Razvi ES
IDrugs; 2005 Oct; 8(10):796-8. PubMed ID: 16254794
[No Abstract] [Full Text] [Related]
4. Drug discovery technology Europe 2006 - IBC's Tenth Annual Conference and Exhibition.
Austin S
IDrugs; 2006 Apr; 9(4):256-60. PubMed ID: 16596477
[No Abstract] [Full Text] [Related]
5. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Protein-protein interactions, biomarkers and RNAi.
Pagliaro L
IDrugs; 2005 Oct; 8(10):793-5. PubMed ID: 16254793
[No Abstract] [Full Text] [Related]
6. [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Yokoba M; Yanase N; Masuda N
Gan To Kagaku Ryoho; 2005 Jun; 32(6):783-8. PubMed ID: 15984516
[TBL] [Abstract][Full Text] [Related]
7. Drug Discovery Technology Europe 2005 - IBC's Ninth Annual Conference and Exhibition.
Austin S
IDrugs; 2005 May; 8(5):370-3. PubMed ID: 15883912
[No Abstract] [Full Text] [Related]
8. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
9. SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.
Chung V; Zhou B; Liu X; Zhu L; Boo LM; Nguyen HV; Ann DK; Song J; Chen Y; Yen Y
Mol Cancer Ther; 2006 Mar; 5(3):533-40. PubMed ID: 16546967
[TBL] [Abstract][Full Text] [Related]
10. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
Katz MH; Takimoto S; Spivack D; Moossa AR; Hoffman RM; Bouvet M
J Surg Res; 2003 Jul; 113(1):151-60. PubMed ID: 12943825
[TBL] [Abstract][Full Text] [Related]
11. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
Kozuch PS; Rocha-Lima CM; Dragovich T; Hochster H; O'Neil BH; Atiq OT; Pipas JM; Ryan DP; Lenz HJ
J Clin Oncol; 2008 May; 26(14):2320-6. PubMed ID: 18467723
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Ding L; Wang HX; Xue M; Zhu L; Liu J; Yan HM; Duan LN; Wang ZD
Leuk Res; 2009 Sep; 33(9):e170-2. PubMed ID: 19403168
[No Abstract] [Full Text] [Related]
15. Novel agents for multiple myeloma treatment.
Ribatti D; Vacca A
Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
[No Abstract] [Full Text] [Related]
16. Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.
Holtan SG; Steen PD; Foster NR; Erlichman C; Medeiros F; Ames MM; Safgren SL; Graham DL; Behrens RJ; Goetz MP
PLoS One; 2012; 7(7):e39285. PubMed ID: 22815703
[TBL] [Abstract][Full Text] [Related]
17. Drug Discovery Technology Europe 2004--IBC's Eighth Annual Conference and Exhibition. 9-10 March 2003, London, UK.
Austin S
IDrugs; 2004 Apr; 7(4):334-8. PubMed ID: 15057639
[No Abstract] [Full Text] [Related]
18. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
19. Activity of bortezomib in advanced non-small-cell lung cancer.
Reddy KG
Clin Lung Cancer; 2004 Nov; 6(3):141-2. PubMed ID: 15555213
[No Abstract] [Full Text] [Related]
20. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
